Information Provided By:
Fly News Breaks for January 29, 2018
MYGN
Jan 29, 2018 | 07:04 EDT
Goldman analyst Patrick Donnelly initiated Myriad Genetics with a Sell and $32 price target citing "extended" valuation and excess optimism around GeneSight reimbursement.
News For MYGN From the Last 2 Days
There are no results for your query MYGN